Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (opens the original source in a new tab)
New England Journal of Medicine
- Design
- Phase 3, double-blind, randomised, placebo-controlled trial; 80 weeks. Weight endpoints used a treatment-regimen intention-to-treat estimand.
- Population / setting
- Adults with obesity without diabetes; prespecified subgroups included participants with knee osteoarthritis or obstructive sleep apnoea.
- Sample size
- n = 2,339
What was observed
At week 80, mean weight changes were −17.6%, −23.7% and −25.0% in the three retatrutide groups versus −3.9% with placebo. The two higher groups differed from placebo by −19.8 and −21.0 percentage points. Gastrointestinal events were the most common adverse events.
Keep in view
These weight results are intention-to-treat estimates; the paper uses a different hybrid estimand for osteoarthritis and sleep-apnoea endpoints. This is not a head-to-head comparison with other medicines or evidence of multi-year safety. Publication is not marketing authorisation. Funded by Eli Lilly.
WHY THIS SOURCE IS HERE
- When does a peptide trial deserve a headline?
Edition 01 examines how to separate a meaningful advance in evidence from a louder version of an existing claim.